PMC:7228307 / 26478-26683
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
470 | 183-186 | Gene | denotes | BCR | Gene:613 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T262 | 85-89 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T263 | 128-133 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T50 | 43-46 | Disease | denotes | MOA | http://purl.obolibrary.org/obo/MONDO_0016702 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T509 | 85-89 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T510 | 90-100 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activating |
T511 | 128-133 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T512 | 162-164 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T141 | 101-110 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T157 | 15-23 | http://purl.obolibrary.org/obo/BFO_0000034 | denotes | function |
T158 | 85-89 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
T159 | 128-133 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cells |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
470 | 183-186 | Gene | denotes | BCR | Gene:613 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T153 | 0-205 | Sentence | denotes | The inhibitory function contributes to the MOA of therapeutic antibodies that target cell‐activating molecules where the target cells also express the inhibitory FcγRIIbs such as the BCR (discussed later). |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T261 | 85-89 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T262 | 128-133 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sample-PD-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T12 | 198-203 | http://purl.obolibrary.org/obo/MAT_0000488 | denotes | later |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T153 | 0-205 | Sentence | denotes | The inhibitory function contributes to the MOA of therapeutic antibodies that target cell‐activating molecules where the target cells also express the inhibitory FcγRIIbs such as the BCR (discussed later). |